written on 26.06.2014
Tags:
,

Biogen MS blockbuster Tecfidera earns high marks for safety

TAGS: ,

Biogen's multiple sclerosis drug Tecfidera has racked up $1.38 billion in sales since its launch last April, and now the company can claim another feather in the drug's cap: It has the best safety profile of any of its peers. That's the conclusion of a new report out from AdverseEvents, which analyzes side-effects data filed with the FDA.

Latest Report